For an updated list, please see PubMed

 

Smalley I , Chen Z , Phadke M, Wyatt C, Law W, Eroglu Z, Tran N, Forsyth P, Chen YA , Smalley KSM . Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Clinical Cancer Research. Epud ahead of print May 25, 2021. # Contributed equally. *Corresponding author.

Phadke, M.S., Chen, Z., Li, J., Mohamed, E., Davies, M.A., Smalley, I., Duckett, D., Palve, V., Czernieck,i B.J., Forsyth, P.A., Noyes, D., Adeegbe, D.O., Eroglu, Z., Nguyen, K.T., Tsai, K.Y., Rix, U., Burd, C.E., Chen, Y.A., Rodriguez, P.C., Smalley, K.S.M.: Targeted therapy given after anti-PD-1 leads to prolonged responses in mouse melanoma models through sustained antitumor immunity. Cancer Immunol Res. 2021. 2021 May;9(5):554-567.

Law, V., Baldwin, M., Ramamoorthi, G., Kodumudi, K., Tran, N., Smalley, I., Duckett, D., Kalinski, P., Czerniecki, B., Smalley, K. S. M., Forsyth, P. A. A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease. J. Vis. Exp. (167), e62033. Jan 29, 2021.

Zhang C, Smalley I*, Emmons MF, Sharma R, Izumi V, Messina J, Koomen JM, Pasquale EB, Forsyth PA, Smalley KSM* https://www.sciencedirect.com/science/article/pii/S0022202X20320479 Journal for Investigative Dermatology. 2020 Sep 2;S0022- 202X(20)32047-9 *Corresponding author.

Smalley I, Law V, Wyatt C, Fang B, Koomen, JM, Welsh E, Macaulay R, Forsyth PA, Smalley KSM. Serial proteomic analysis of CSF from patients with leptomeningeal melanoma metastases identifies signatures associated with disease progression and mediators of therapy resistance. Clin Cancer Res. 2020 Jan 10. Epub ahead of print.

Glitza I, Smalley K, Brastianos P, Davies M, McCutcheon I, Liu J, Ahmed K, Arrington J, Evernden B, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins M, Tawbi H, Boire A, Forsyth P. Leptomeningeal Disease in Melanoma Patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Research 2020 Jul;33(4):527-541.

Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Erolgu Z, Sondak VK, Messina JL, Babacan NA, Maria-Engler SS, De Armas L, Williams SL, Gatenby RA, Chen YA, Anderson ARA, Smalley KSM. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. eBioMedicine. 2019 Oct;48:178-190.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019 May;32(3):458-469.

Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma. Clin Cancer Res. 2018 Nov 15;24(22):5516-5524.

Smalley I, Smalley KSM. ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers? Cancer Discov. 2018 Feb;8(2):140-142.

Abate-Daga D, Ramello MC, Smalley I, Forsyth PA, Smalley KSM. The biology and therapeutic management of melanoma brain metastases. Biochem Pharmacol. 2018 Jul;153:35-45.

Phadke M, Remsing Rix LL, Smalley I, Bryant AT, Luo Y, Lawrence HR, Schaible BJ, Chen YA, Rix U, and Smalley KSM. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Molecular Oncology. Mol Oncol. 2018 Jan;12(1):74-88.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res. 2017 Dec;27(6):545-557

Li J, Smalley I, Schell MJ, Smalley KSM, Chen YA. SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. Bioinformatics. 017 Sep 15;33(18):2951-2953

Sharma R*, Fedorenko I*, Spence PT, Sondak VK, Smalley KS, Koomen JM. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. J Proteome Res. 2016 Dec 2;15(12):4476-4489. *Co-first authors

Fedorenko IV, Evernden B, Kenchappa RS, Sahebjam S, Ryzhova E, Puskas J, Mcintosh L, Caceres G, Magliocco  A, Etame A, Harbour JW, Smalley KSM, Forsyth PA. A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.  Melanoma Research. 2016 Oct;26(5):481-6.

Smalley KSM, Fedorenko IV, Kenchappa R, Sahebjam S, Forsyth P. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. International Journal of Cancer. February 2016. 2016 Sep 15;139(6):1195-201

Fedorenko IV*, Smalley KSM. The complexity of microenvironment-mediated drug resistance. Genes Cancer. 2015 Sep;6(9-10):367-368. *Corresponding author.

Fedorenko IVWargo JA, Flaherty KT, Smalley KSM. BRAF inhibition generates a host/tumor niche that mediates therapeutic escape. J Invest Derm. 2015 Aug 24. 2015 Dec;135(12):3115-24.

Phadke, M., Gibney, G., Rich, C., Fedorenko, I.V., Chen A., Kudchadkar, R., Sondak, V.K., Weber, J., Messina, J., Smalley, K.S.M.: XL888 limits vemurafenib-induced prolifetaive skin events by suppressing paradoxical MAPK activation. J Invest Derm. 2015 Oct;135(10):2542-4.

Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen A, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KSM. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar 10;35(10):1225-35.

Smalley KSM and Fedorenko IV. Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma. Molecular & Cellular Oncology, 2015 Mar 19;2(4)

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand independent EphA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar;5(3):264-73.

Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where to next for melanoma targeted therapy? Br J Cancer. 2015 Jan 20;112(2):217-26.

Fedorenko IV, Fang B, Munko AC, Paraiso KHT, Gibney GT, Koomen JM, Smalley KS. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics. 2015 Jan;15(2-3):327-39.

Fedorenko IV, Fang, B, Koomen, JM, Gibney, GT, Smalley, KS. Amuvatinib has cytotoxic effects against NRAS but not BRAF mutant melanoma. Melanoma Research. 2014 Oct;24(5):448-53.

Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. Mol Cell Proteomics. 2014 Jul;13(7):1844-54

Rebecca VW, Massaro R, Fedorenko IV, Gibney GT, Sondak VK, Amavaradi RK, Jin S, Maria-Engler SS, Kudchadkar RR, Smalley KSM: Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell and Melanoma Research 2014 May;27(3):465-78.

Sloot S, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother. 2014 Apr;15(5):589-92

Kim E, Rebecca V, Fedorenko IV, Messina JL, Mathew R, Maria-Engler SS, Basanta D, Smalley KS, Anderson AR. Senescent Fibroblasts in Melanoma Initiation and Progression: An Integrated Theoretical, Experimental, and Clinical Approach. Cancer Res. 2013 Dec 1;73(23):6874-85.

Pimiento JM, Larkin EM, Smalley KS, Wiersma GL, Monks NR, Fedorenko IV, Peterson CA, Nickoloff BJ. Melanoma genotypes and phenotypes get personal. Lab Invest. 2013 Aug;93(8):858-67. Featured on cover.

Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis–the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013 Jul;10(7):390-9.

Fedorenko IV, Gibney GT, Smalley KSM. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013 Jun 20;32(25):3009-18

Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol. 2011 Aug 1;82(3):201-9.

Paraiso K.H.T., Xiang Y., Rebecca V., Abel E.V., Chen Y.A., Munko A.C., Wood E., Fedorenko IV, Sondak V.K., Anderson A.R.A, Ribas A., Palma M.D., Nathanson K.L, Koomen J.M., Messina J.L., Smalley K.S.M. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Can Res. 2011 Apr 1;71(7):2750-60. Epub 2011 Feb 11. As highlighted in Nature Rev Clin Oncol. 2011 May;8(5):253.

Paraiso K.H.T., Fedorenko, I.V. , Cantini, L.P., Munko, A. C., Hall, M. S., Sondak, V. K., Messina, J. L., Flaherty, K.T.,  Smalley, K. S. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010 Jun 8;102(12):1724-30.

Song D., Fedorenko I., Pensky M., Qian W., Tockman M., Zhukov T. Quantificational and Statistical Analysis of the Differences in Centrosomal Features of Untreated Lung Cancer Cells and Normal Cells. Analytical and Quantitative Cytology and Histology 2009 Oct 32 (5) 280-290.

Liu X., Lloyd M. C., Fedorenko I. V., Bapat P., Zhukov T., Huo Q. Enhanced imaging and accelerated photothermolysis of A549 human lung cancer cells by gold nanospheres. Nanomedicine 2008 Oct: 3(5): 617-26